» Articles » PMID: 32152232

Atorvastatin Reduces Fibrin Deposition and Macrophage Accumulation, and Improves Primary Patency Duration and Maturation of Murine Arteriovenous Fistula

Overview
Specialty Nephrology
Date 2020 Mar 11
PMID 32152232
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Arteriovenous fistulas placed surgically for dialysis vascular access have a high primary failure rate resulting from excessive inward remodeling, medial fibrosis, and thrombosis. No clinically established pharmacologic or perisurgical therapies currently address this unmet need. Statins' induction of multiple anti-inflammatory and antithrombotic effects suggests that these drugs might reduce arteriovenous fistula failure. Yet, the physiologic and molecular effects of statins on fistula patency and maturation remain poorly understood.

Methods: We randomized 108 C57Bl/6J mice to receive daily atorvastatin 1.14 mg/kg or PBS (control) starting 7 days before end-to-side carotid artery-jugular vein fistula creation and for up to 42 days after fistula creation. We then assessed longitudinally the effects of statin therapy on primary murine fistula patency and maturation. We concomitantly analyzed the arteriovenous fistula thrombogenic and inflammatory macrophage response to statin therapy, using the fibrin-targeted, near-infrared fluorescence molecular imaging agent FTP11-CyAm7 and dextranated, macrophage-avid nanoparticles CLIO-VT680.

Results: molecular-structural imaging demonstrated that atorvastatin significantly reduced fibrin deposition at day 7 and macrophage accumulation at days 7 and 14, findings supported by histopathologic and gene-expression analyses. Structurally, atorvastatin promoted favorable venous limb outward remodeling, preserved arteriovenous fistula blood flow, and prolonged primary arteriovenous fistula patency through day 42 (<0.05 versus control for all measures).

Conclusions: These findings provide new evidence that statins improve experimental arteriovenous fistula patency and maturation, indicating that additional clinical evaluation of statin therapy in patients on dialysis undergoing arteriovenous fistula placement is warranted.

Citing Articles

Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency.

Baranwal G, Mukhtar H, Kane J, Lemieux A, Misra S Int J Mol Sci. 2024; 25(23).

PMID: 39684430 PMC: 11641758. DOI: 10.3390/ijms252312719.


Correlation between pre-operative VE-cadherin and DLL4 and the maturation after primary arteriovenous fistula in uremic patients.

Yin H, Tang Y, Wang Y, Waheed Y, Wang D, Sun D PeerJ. 2024; 12:e18356.

PMID: 39583102 PMC: 11585290. DOI: 10.7717/peerj.18356.


The Role of Cardio-Renal Inflammation in Deciding the Fate of the Arteriovenous Fistula in Haemodialysis Therapy.

Kane J, Lemieux A, Baranwal G, Misra S Cells. 2024; 13(19.

PMID: 39404400 PMC: 11475948. DOI: 10.3390/cells13191637.


The Pathological Mechanisms and Therapeutic Molecular Targets in Arteriovenous Fistula Dysfunction.

Yan R, Song A, Zhang C Int J Mol Sci. 2024; 25(17).

PMID: 39273465 PMC: 11395150. DOI: 10.3390/ijms25179519.


Factors affecting suboptimal maturation of autogenous arteriovenous fistula in elderly patients with diabetes:A narrative review.

Liu S, Wang Y, He X, Wang Y, Li X Heliyon. 2024; 10(15):e35766.

PMID: 39170451 PMC: 11337043. DOI: 10.1016/j.heliyon.2024.e35766.


References
1.
OShea S, Lawson J, Reddan D, Murphy M, Ortel T . Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg. 2003; 38(3):541-8. DOI: 10.1016/s0741-5214(03)00321-5. View

2.
Chang C, Ko Y, Ko P, Hsu L, Chen C, Yang C . Thrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int. 2005; 68(3):1312-9. DOI: 10.1111/j.1523-1755.2005.00529.x. View

3.
Motwani J, Topol E . Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998; 97(9):916-31. DOI: 10.1161/01.cir.97.9.916. View

4.
Schonbeck U, Libby P . Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation. 2004; 109(21 Suppl 1):II18-26. DOI: 10.1161/01.CIR.0000129505.34151.23. View

5.
Brahmbhatt A, Remuzzi A, Franzoni M, Misra S . The molecular mechanisms of hemodialysis vascular access failure. Kidney Int. 2016; 89(2):303-316. PMC: 4734360. DOI: 10.1016/j.kint.2015.12.019. View